查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864642

皮膚絲狀菌症治療市場按產品類型、藥物類別、分銷管道、最終用戶和治療用途分類－2025-2032年全球預測

Dermatophytosis Treatment Market by Product Type, Drug Class, Distribution Channel, End User, Treatment Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，皮膚絲狀菌症治療市場將成長至 214.2 億美元，複合年成長率為 6.10%。

關鍵市場統計數據
基準年 2024 133.3億美元
預計年份：2025年 141.4億美元
預測年份 2032 214.2億美元
複合年成長率 (%) 6.10%

全面介紹影響現代皮膚絲狀菌症治療決策的臨床挑戰和商業性趨勢，這些挑戰和趨勢涉及各相關人員。

皮膚絲狀菌症仍然是全球持續存在的臨床挑戰，其成因包括環境暴露、人口流動以及治療方案的不斷演變。患者和臨床醫生必須治療方法，每種藥物的製劑特性、依從性和耐受性各不相同。在此背景下，從製藥企業到醫院採購團隊等各相關人員必須權衡臨床療效與實際因素，例如患者的依從性、就診皮膚科醫生的機會以及正在改變處方和配藥方式的數位化管道的出現。

診斷技術的進步、藥物類別的發展趨勢以及分銷管道的創新如何重塑皮膚絲狀菌症的治療選擇和競爭優勢

皮膚絲狀菌症治療領域正經歷多重變革，這些變革正在改變治療路徑和商業模式。診斷工具的進步，包括照護現場和遠端皮膚病學平台，正在縮短診斷時間，並使標靶治療成為可能。因此，治療路徑越來越注重適合門診和遠端醫療環境的製劑和給藥方案，這促使生產商調整產品系列，也促使醫院和診所重新評估其採購標準。

評估貿易政策和關稅變化對皮膚絲狀菌症治療相關人員在營運、採購和商業性的影響鏈

2025年即將實施的關稅政策環境對皮膚絲狀菌症治療藥物的供應商、製造商和經銷商產生了連鎖反應。進口關稅的增加和貿易摩擦加劇了投入成本的波動，尤其是活性藥物成分和特殊輔料，這些原料的生產集中在某些地區。為了因應這種情況，製造商正在調整籌資策略，透過供應商多元化、重新評估庫存政策，以及在某些情況下加快對區域生產能力的投資，來降低跨境價格波動帶來的風險。

透過整合產品形態、藥理分類、通路和臨床應用等因素進行細分分析，最佳化策略定位。

深入了解細分市場的動態動態對於使產品策略與實際使用情況和分銷通路特徵相符至關重要。依產品類型分類，可區分口服和外用療法。口服劑型通常包括膠囊、混懸劑和錠劑，而外用劑型則包括乳膏、凝膠、軟膏和粉末。每種劑型都有其獨特的依從性和應用的考慮，這些因素會影響臨床偏好和患者滿意度。依藥物類別分類，可突顯Allylamines和Azole兩大藥理家族。這兩大家族具有不同的作用頻譜和交互作用特徵，這會影響醫師針對不同患者族群的用藥選擇。

區域策略意義：監管多樣性、分銷管道成熟度和數位化應用如何影響各區域治療皮膚絲狀菌症的方法

區域趨勢正顯著影響著美洲、歐洲、中東和非洲以及亞太地區的法規環境成熟度、醫療基礎設施和分銷管道。在美洲，完善的醫療體系和成熟的零售藥房網路支持患者廣泛獲取外用和口服藥物，而不斷普及的數位化藥房則為直接與患者互動和提供患者支持服務創造了機會。該地區公立和私立醫院的採購慣例對藥品目錄的製定和批量採購模式有重大影響。

競爭格局凸顯了配方創新、供應鏈韌性和數位化協作對於確立皮膚絲狀菌症治療領域領導地位的重要性。

皮膚絲狀菌症治療領域的競爭格局由眾多機構共同塑造，包括跨國製藥公司、皮膚科專科藥品生產商、學名藥生產商、原料藥供應商以及數位藥局平台。領導企業透過配方創新提升患者依從性和皮膚生物利用度，從而實現差異化競爭；而其他企業則在成本和供應可靠性方面展開競爭，尤其是在對採購價格高度敏感的環境下。配方研發商與數位醫療服務提供者之間的合作日益重要，有助於提高患者依從性、遠距離診斷和進行患者教育，這些合作構成了超越藥物本身的附加價值服務的核心組成部分。

領導者可採取切實可行的策略重點，以協調配方創新、通路執行和供應鏈韌性，從而滿足不斷變化的臨床和商業性需求。

產業領導者應優先考慮將臨床價值提案與營運能力和通路策略結合的綜合措施。首先，投資配方和以患者為中心的包裝創新，以降低給藥複雜性並提高患者依從性，同時將臨床數據與真實世界證據研究相結合，以證明在門診和居家醫療環境中差異化的治療效果。其次，增強供應商多元化和區域生產選擇，以降低貿易相關的成本波動，並確保按時向醫院和零售網路交付產品。

我們利用透明的調查方法和混合方法檢驗技術，以確保在臨床、商業和供應鏈層面獲得穩健、可操作的見解。

本研究採用混合方法進行綜合分析，將質性一手研究與量化二手研究結合，以得出可操作的見解。一手研究包括對皮膚科醫生和全科醫生、公立和私立醫院的採購經理以及製造商和經銷商的商業主管進行結構化訪談。這提供了關於處方行為、藥物採納決定因素和通路經濟效益的實地觀點。此外，還對數位藥房平台進行了觀察分析，並檢驗了供應鏈文檔，以了解營運限制和分銷趨勢。

總結性回顧摘要，臨床創新、不斷發展的通路和供應鏈韌性如何共同決定皮膚絲狀菌症治療的競爭結果。

總之，臨床、商業性和政策力量的共同作用正在重塑皮膚絲狀菌症的治療模式。診斷技術的進步和遠距遠端醫療的普及使得疾病早期即可進行治療，改變了外用和口服藥物的選擇標準，並提升了患者友善製劑的重要性。Allylamines和Azole藥物分類將繼續指導處方醫生的選擇，而劑型創新則有望在活性成分之外創造顯著的差異化優勢。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大採用抗真菌聯合治療來對抗抗藥性皮癬菌菌株
  • 增加對新型局部奈米載體遞送系統的投資，用於定向抗真菌治療
  • 非處方抗真菌藥物銷量激增，其先進配方提高了療效。
  • 在整合數位皮膚病學平台以進行皮膚感染疾病的遠距離診斷和管理方面取得了進展
  • 雷射療法和動態療法作為難治性皮膚絲狀菌症輔助治療的進展
  • 專注於研發療程更短、安全性更高的口服抗黴菌藥物。
  • 利用皮癬菌屬的基因譜進行標靶治療，正在湧現一些個人化治療方法。
  • 嚴格的監管要求推動了新型皮膚絲狀菌症病治療藥物臨床試驗設計的創新。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的皮膚絲狀菌症病治療市場

  • 口服
    • 膠囊
    • 暫停
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 軟膏
    • 粉末

第9章 依藥物類別分類的皮膚絲狀菌症病治療市場

  • Allylamines藥物
  • Azole

第10章 依分銷管道分類的皮膚絲狀菌症治療市場

  • 醫院藥房
    • 私人的
    • 民眾
  • 網路藥房
    • 電子處方箋
    • OTC
  • 零售藥房
    • 鏈
    • 獨立的

第11章 依最終使用者分類的皮膚絲狀菌症病治療市場

  • 診所
    • 皮膚科診所
    • 一般診所
  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 依治療應用分類的皮膚絲狀菌症病治療市場

  • 足癬
  • 股癬
  • 癬
  • 花斑癬

第13章 各地區皮膚絲狀菌症病治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 依組別分類的皮膚絲狀菌症病治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國皮膚絲狀菌症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • GlaxoSmithKline plc
    • Bayer AG
    • Johnson & Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Limited
    • Lupin Limited
    • Viatris Inc.
    • Torrent Pharmaceuticals Limited
Product Code: MRR-7A22CB0E5C75

The Dermatophytosis Treatment Market is projected to grow by USD 21.42 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.33 billion
Estimated Year [2025] USD 14.14 billion
Forecast Year [2032] USD 21.42 billion
CAGR (%) 6.10%

An integrated introduction to the clinical challenges and commercial dynamics that underpin contemporary dermatophytosis treatment decision-making across stakeholders

Dermatophytosis remains a persistent clinical challenge globally, driven by a combination of environmental exposure, demographic mobility, and evolving treatment pathways. Patients and clinicians navigate a complex array of topical and systemic options, each with distinct formulation, compliance, and tolerability implications. Against this backdrop, stakeholders from pharmaceutical manufacturers to hospital procurement teams must reconcile clinical efficacy with real-world factors such as adherence, access to dermatology specialists, and the emergence of digital channels that change how therapy is prescribed and dispensed.

Clinical practice is adapting as diagnostic capabilities and teledermatology expand, enabling earlier recognition and differentiation among athlete's foot, jock itch, ringworm, and tinea versicolor. This shift toward earlier intervention has meaningful implications for treatment selection and duration of therapy, and it places a premium on formulations that combine ease of use with reliable pharmacologic profiles. Meanwhile, regulatory attention to generic substitution and bioequivalence remains a defining influence on product rollout strategies.

From the commercial perspective, manufacturers must integrate product design, supply chain resilience, and channel strategies to maintain competitive positioning. The interplay of oral and topical modalities, distinct drug classes with differing safety and interaction profiles, and a diversifying distribution landscape requires an integrated approach to market entry, product lifecycle management, and stakeholder engagement. This introduction frames the strategic questions that follow and prepares readers to understand how shifts in regulation, trade policy, and consumer behavior are reshaping the dermatophytosis treatment ecosystem.

How diagnostic advances, drug class dynamics, and channel innovation are reshaping therapeutic choices and competitive advantages in dermatophytosis care

The dermatophytosis landscape is experiencing several transformative shifts that alter both treatment pathways and commercial models. Advances in diagnostic tools, including point-of-care assessments and teledermatology platforms, are accelerating time-to-diagnosis and enabling targeted therapy selection. As a result, treatment pathways increasingly favor formulations and dosing regimens that align with outpatient and remote-care settings, prompting portfolio adjustments from manufacturers and revised procurement criteria within hospitals and clinics.

At the same time, drug-class dynamics are evolving. Clinical preference patterns for allylamines and azoles reflect differences in spectrum of activity, safety profile, and perceived relapse rates, prompting prescribers to refine selection criteria based on patient comorbidities and potential drug interactions. This clinical evolution is mirrored by formulation innovation that emphasizes patient convenience, enhanced dermal penetration, and tolerability, creating differentiation beyond active pharmaceutical ingredient alone.

Distribution is also in flux as online pharmacies and e-prescription models gain traction, shifting volume away from traditional retail footprints and creating new demands for digital patient support and adherence solutions. Concurrently, supply chain optimization and sourcing diversification are becoming strategic priorities in response to geopolitical pressures and raw material variability. Together, these forces are redefining competitive advantage, with companies that integrate clinical evidence, digital engagement, and resilient sourcing positioned to capture the most sustainable opportunities.

Assessing the cascading operational, procurement, and commercial consequences of trade policy and tariff shifts for dermatophytosis treatment stakeholders

The policy environment surrounding tariffs introduced in 2025 has cascading implications for suppliers, manufacturers, and distributors linked to dermatophytosis treatment. Increased import duties and trade frictions amplify input cost volatility, particularly for active pharmaceutical ingredients and specialized excipients that are produced in concentrated geographies. In response, manufacturers have adjusted procurement strategies to diversify supplier bases, re-evaluate inventory policy, and, in some cases, accelerate investments in regional manufacturing capacity to reduce exposure to cross-border pricing shocks.

Price pressures created by tariff-driven cost increases have influenced commercial decisions across distribution channels. Hospital procurement teams have responded by tightening formulary criteria and seeking procurement efficiencies, while retail and online pharmacies have reassessed margin structures and promotional tactics. The result is a renewed emphasis on cost-to-serve analysis and more rigorous contract terms with both upstream suppliers and downstream channel partners.

Regulatory and compliance burdens have also shifted in importance as trade-related documentation and customs scrutiny demand greater administrative capacity. Companies with integrated supply-chain visibility and proactive customs management have gained operational advantages. Moreover, tariffs have accelerated conversations about nearshoring and capacity redundancy; yet, these transitions require multiyear planning, capital, and regulatory alignment. Ultimately, the tariff environment has elevated resilience and flexibility as core competencies for organizations operating in the dermatophytosis treatment space.

Integrated segmentation insights linking product formats, pharmacologic classes, distribution pathways, and clinical applications to optimize strategic positioning

A nuanced understanding of segment-specific dynamics is essential to align product strategy with real-world use and channel behaviors. Product-type segmentation differentiates oral and topical therapies, with oral options typically available as capsules, suspensions, and tablets while topical formats include creams, gels, ointments, and powders, each format carrying unique adherence and application considerations that shape clinical preference and patient satisfaction. Drug-class segmentation highlights allylamines and azoles, two pharmacologic families that diverge on spectrum of activity and interaction profiles, informing prescriber choice for distinct patient populations.

Distribution channels present distinct operational and commercial imperatives. Hospital pharmacies operate across private and public settings and respond to institutional procurement cycles and formulary governance, whereas online pharmacies are split between e-prescription models and over-the-counter access, demanding digital engagement strategies and logistics optimization. Retail pharmacies differentiate between chain and independent operators, each with specific stocking, promotional, and relationship models that affect new product uptake. End-user segmentation separates clinics-both dermatology-focused and general practice-homecare settings, and hospitals divided into private and public institutions, with each care setting imposing different expectations for treatment duration, dispensing unit sizes, and patient counseling.

Treatment application segmentation distinguishes common indications such as athlete's foot, jock itch, ringworm, and tinea versicolor, and each presentation influences formulation preference, dosing duration, and the likelihood of seeking specialist care. An integrated segmentation view reveals that product design, channel strategy, and clinical positioning must be tightly coordinated to meet the heterogeneous demands of providers, payers, and patients.

Regional strategic implications showing how regulatory diversity, channel maturity, and digital adoption shape dermatophytosis treatment approaches across global regions

Regional dynamics exert clear influence on regulatory environments, healthcare infrastructure, and channel maturation across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, established healthcare systems and a mature retail pharmacy network support broad access to both topical and oral therapies, while digital pharmacy adoption continues to expand, creating opportunities for direct-to-patient engagement and patient support services. Public and private hospital procurement practices in this region exert meaningful influence on formulary decisions and large-volume purchasing patterns.

In Europe, Middle East & Africa, regulatory complexity varies significantly across national jurisdictions, prompting multinational manufacturers to adopt differentiated registration and pricing strategies. Hospital and clinic procurement models in parts of this region emphasize cost-effectiveness and centralized purchasing, and digital health adoption is accelerating in urban centers even as supply chain constraints persist in certain markets. Meanwhile, private clinics with dermatology specialization can serve as early adopters for novel formulations and adherence-support programs.

The Asia-Pacific region presents a highly heterogeneous landscape with rapid growth in telemedicine, a high prevalence of dermatologic conditions tied to climatic factors, and an expanding manufacturing base for active ingredients and finished dosage forms. Evolving regulatory harmonization efforts and expanding online pharmacy infrastructure are enabling faster channel diversification. Across all regions, successful commercialization requires tailored regulatory engagement, nuanced channel strategies, and sensitivity to local prescribing practices and patient preferences.

Competitive landscape analysis revealing how formulation innovation, supply resilience, and digital partnerships define leadership in dermatophytosis treatment

Competitive dynamics in dermatophytosis treatment are shaped by a spectrum of organizations ranging from multinational pharmaceutical firms to specialty dermatology manufacturers, generic producers, API suppliers, and digital pharmacy platforms. Leading players differentiate through formulation innovation that enhances patient adherence and dermal bioavailability, while others compete on cost and supply reliability, particularly in settings where procurement is price-sensitive. Collaboration between formulators and digital health providers has become increasingly important to support adherence, remote diagnosis, and patient education, creating a nexus for value-added services beyond the pill or cream itself.

Supply-side actors such as contract manufacturers and API producers exert outsize influence on production flexibility and lead times, and their geographic footprint shapes cost structures and responsiveness to trade-related disruptions. Companies that have invested in quality management systems, serialization, and cold-chain-adjacent logistics for sensitive excipients have obtained differentiation in institutional procurement processes. On the commercial front, firms that deploy targeted medical affairs programs and build strong relationships with dermatology societies and clinic networks can accelerate clinical uptake and sustain product positioning.

Overall, the competitive set rewards those that combine clinical evidence generation, operational resilience, and digitally-enabled patient engagement. Strategic alliances, licensing arrangements, and selective M&A activity have been used to accelerate access to differentiated formulations, bolster distribution networks, and shore up manufacturing capacity in response to both clinical needs and macroeconomic pressures.

Actionable strategic priorities for leaders to align formulation innovation, channel execution, and supply resilience with evolving clinical and commercial demands

Industry leaders should prioritize an integrated set of actions that align clinical value proposition with operational capabilities and channel strategies. First, invest in formulation and patient-centric packaging innovations that reduce application complexity and support adherence, while pairing clinical data with real-world evidence studies to substantiate differentiated outcomes in outpatient and homecare settings. Second, strengthen supplier diversification and regional manufacturing options to mitigate trade-related cost volatility and ensure on-time delivery to hospitals and retail networks.

Next, develop channel-specific commercialization plans: build digital-first patient support and e-prescription integrations to capture growing online demand while deepening relationships with hospital pharmacy procurement teams through value-based contracting pilots and targeted educational initiatives for dermatology clinics. Concurrently, pursue partnerships with contract manufacturers or API producers to secure preferential capacity and enable rapid scale-up for high-demand formulations. Additionally, enhance medical affairs presence to support guideline inclusion and to educate prescribers on nuanced drug-class selection between allylamines and azoles.

Finally, embed agility into commercial operations by adopting advanced analytics for demand sensing, refining cost-to-serve models for each distribution pathway, and creating cross-functional rapid-response teams that can execute scenario-based supply and pricing adjustments. Executed together, these steps will improve resilience, accelerate uptake of differentiated products, and protect margin in an increasingly complex global environment.

Methodological transparency and mixed-methods validation techniques used to ensure robust, actionable insights across clinical, commercial, and supply-chain dimensions

This research synthesis leverages a mixed-methods approach that integrates primary qualitative engagement with quantitative secondary intelligence to produce actionable insights. Primary inputs included structured interviews with clinicians across dermatology and general practice, procurement leaders from private and public hospitals, and commercial executives from manufacturers and distributors, providing frontline perspectives on prescribing behavior, formulary decision drivers, and channel economics. These interviews were complemented by observational analysis of digital pharmacy platforms and supply-chain documentation to capture operational constraints and distribution trends.

Secondary analysis drew upon authoritative regulatory publications, clinical guidelines, pharmacology references, and peer-reviewed literature to validate clinical assertions and to map the differentiating profiles of allylamines and azoles. Data triangulation was applied to reconcile variations across regional practices and to ensure that segmentation frameworks accurately reflect how product format, channel, and end-user behaviors intersect. Quality assurance measures included cross-validation of interview findings with documented procurement policies and independent expert review to reduce bias.

The methodology emphasizes transparency and reproducibility. Assumptions and definitions for segmentation and regional categorizations were explicitly documented, and sensitivity checks were performed to evaluate operational scenarios under different supply-chain and policy conditions. These methodological steps ensure that the insights presented are robust, contextually grounded, and actionable for commercial and clinical decision-makers.

Concluding synthesis summarizing how clinical innovation, channel evolution, and supply-chain resilience collectively determine competitive outcomes in dermatophytosis care

In closing, the dermatophytosis treatment environment is being reshaped by converging clinical, commercial, and policy forces. Diagnostic advances and telehealth expansion are moving care earlier in the disease course, changing the calculus for topical versus oral choice and increasing the importance of patient-friendly formulations. Drug-class distinctions between allylamines and azoles continue to guide prescriber selection, and innovation in delivery formats can create meaningful differentiation beyond the active ingredient alone.

Concurrently, distribution channels are fragmenting, with online pharmacies and e-prescription models gaining share while hospital and retail procurement practices evolve under cost and compliance pressures. Trade policy and tariff developments have injected additional operational complexity, elevating the strategic importance of supplier diversification, regional manufacturing, and advanced procurement capabilities. Competitive advantage today accrues to organizations that combine clinical evidence, resilient supply chains, and digitally enabled patient engagement.

Moving forward, stakeholders should prioritize integrated strategies that align product development, channel access, and operational resilience. With clear clinical positioning and adaptive commercial execution, manufacturers and distributors can navigate policy headwinds, meet diverse patient needs, and sustain long-term value creation in the dermatophytosis treatment space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of combination antifungal therapies to combat resistant dermatophyte strains
  • 5.2. Increased investment in novel topical nanocarrier delivery systems for targeted antifungal treatment
  • 5.3. Surge in over-the-counter fungal treatments with advanced formulation technologies for improved efficacy
  • 5.4. Growing integration of digital dermatology platforms for remote diagnosis and management of skin infections
  • 5.5. Advancements in laser and photodynamic therapies as adjunct treatments for recalcitrant dermatophytosis
  • 5.6. R&D focus on oral antifungal alternatives offering shorter treatment durations and enhanced safety profiles
  • 5.7. Emergence of personalized treatment approaches using genetic profiling of dermatophyte species for targeted therapy
  • 5.8. Stringent regulatory requirements driving innovation in clinical trial designs for new dermatophytosis drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dermatophytosis Treatment Market, by Product Type

  • 8.1. Oral
    • 8.1.1. Capsules
    • 8.1.2. Suspensions
    • 8.1.3. Tablets
  • 8.2. Topical
    • 8.2.1. Creams
    • 8.2.2. Gels
    • 8.2.3. Ointments
    • 8.2.4. Powders

9. Dermatophytosis Treatment Market, by Drug Class

  • 9.1. Allylamines
  • 9.2. Azoles

10. Dermatophytosis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Online Pharmacies
    • 10.2.1. E Prescription
    • 10.2.2. OTC
  • 10.3. Retail Pharmacies
    • 10.3.1. Chain
    • 10.3.2. Independent

11. Dermatophytosis Treatment Market, by End User

  • 11.1. Clinics
    • 11.1.1. Dermatology Clinics
    • 11.1.2. General Clinics
  • 11.2. Homecare
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Dermatophytosis Treatment Market, by Treatment Application

  • 12.1. Athlete's Foot
  • 12.2. Jock Itch
  • 12.3. Ringworm
  • 12.4. Tinea Versicolor

13. Dermatophytosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dermatophytosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dermatophytosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Bayer AG
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Sanofi SA
    • 16.3.6. Teva Pharmaceutical Industries Ltd.
    • 16.3.7. Dr. Reddy's Laboratories Limited
    • 16.3.8. Lupin Limited
    • 16.3.9. Viatris Inc.
    • 16.3.10. Torrent Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DERMATOPHYTOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DERMATOPHYTOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DERMATOPHYTOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHA